West Pharma (WST) Tops Q4 EPS by 13c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
West Announces Fourth-Quarter and Full-Year 2021 Results
February 17, 2022 6:00 AM ESTEXTON, Pa., Feb. 17, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2021 and introduced full-year 2022 financial guidance.
Fourth-Quarter and Full-Year 2021 Summary (comparisons to prior-year period)
Fourth-quarter 2021 net sales of $730.8 million grew 26.0%; organic sales growth was 28.3%. Full-year 2021 net sales of $2.832 billion... More